Blog posts

New EU Regulatory Recommendations for Decentralized Trials Keep Focus on Patients and Sites

As clinical trials rapidly modernize, government regulators work to evolve even as the same core principles apply. Still, decentralized clinical trials are – simply – clinical trials, as all research today is decentralized in some way, yet we lack global harmonization of regulations.

White Papers, Case Studies, Reports

Tufts CSDD Impact report: Decentralized and hybrid trials deliver greater ROI than traditional trials

6 min

The Tufts Center for the Study of Drug Development completed an analysis of its financial modeling study of decentralized clinical trials  using real data from Medable-enabled studies. These findings net financial benefits ranging from 5x for Phase II and 13x for Phase III trials, equating to roughly $10 million ROI and $39 million ROI, respectively.

See how Medable can make your trials more efficient.